Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 12
Encontrada(s) 1 página(s)

DAU Arxiu Digital de la Universitat Ramon Llull
Publicación Artículo científico (JournalArticle)

Neurochemical and behavioral evidence of high abuse liability of 3F-NEB, a novel synthetic cathinone

  • Pain, Stephanie
  • Nadal-Gratacós, Núria
  • De Macedo, Morgane
  • Lardeux, Virginie
  • Mata, Sandra
  • Puigseslloses, Pol
  • Wang, Fua-Hua
  • Källsten, Liselott
  • Pubill, David
  • Berzosa, Xavier
  • Kehr, Jan
  • Camarasa, Jorge
  • Escubedo, Elena
  • López-Arnau, Raúl
  • THIRIET, Nathalie
  • Solinas, Marcello
Synthetic cathinones constitute a major class of New Psychoactive Substances (NPS) with significant abuse potential. Within this class, 3F-N-ethylbuphedrone (3F-NEB or 2-(ethylamino)-1-(3-fluorophenyl)butan-1-one), a novel N-ethyl buphedrone derivative, has recently emerged in recreational drug markets. However, its pharmacological properties and abuse liability remain uncharacterized. The present study aimed to evaluate the neurochemical mechanisms and behavioral effects of 3F-NEB to assess its potential for abuse and addiction. To this end, we conducted in vitro monoamine uptake inhibition assays and in mice we performed locomotor activity and conditioned place preference tests. In rats, we conducted in vivo microdialysis in the nucleus accumbens, intravenous self-administration, and assessed neuroadaptive changes by ΔFosB immunohistochemistry following chronic self-administration. Our results demonstrate that 3F-NEB acts as a potent dopamine transporter (DAT) inhibitor, with more than 100-fold selectivity over the serotonin transporter (SERT). Acute administration (3 mg/kg) rapidly increased extracellular dopamine levels in the nucleus accumbens of rats. At the behavioral level, 3F-NEB induced dose-dependent locomotor increases (10–30 mg/kg), with anxiety-like effects at the highest doses, and conditioned place preference at all tested doses (3–30 mg/kg) in mice. 3F-NEB was readily self-administered by rats under both fixed-ratio and progressive-ratio schedules. Furthermore, chronic self-administration significantly increased ΔFosB expression in dorsomedial and dorsolateral striatum, mirroring patterns observed with methamphetamine. Taken together, these results demonstrate that 3F-NEB exhibits potent dopaminergic activity and high abuse liability through selective dopamine transporter inhibition. The compound's robust reinforcing properties and induction of addiction-related molecular adaptations suggest significant public health risks warranting immediate regulatory control., info:eu-repo/semantics/publishedVersion
DAU Arxiu Digital de la Universitat Ramon Llull
Publicación Artículo científico (JournalArticle)

Neuropharmacology of halogenated DMT analogs: psychoplastogenic and antidepressant properties of 5-Br-DMT, a psychedelic derivative with low hallucinogenic potential

  • Puigseslloses, Pol
  • Nadal-Gratacós, Núria
  • Fumas, Berta
  • Modenutti, Carlos Pablo
  • Pottie , Eline
  • Ortigosa, Juan Rodrigo
  • Pablo-Quesada, Albert
  • Riera Colomer, Clara
  • Ettcheto, Miren
  • Berzosa, Xavier
  • Pubill, David
  • Stove, Christophe
  • Escubedo, Elena
  • López-Arnau, Raúl
Current first-line antidepressants, such as selective serotonin reuptake inhibitors (SSRI), often present a delayed onset of action and fail to effectively treat a large proportion of patients, leaving a gap in the treatment of mood disorders. Psychedelics have recently emerged as promising alternatives due to their ability to produce fast-acting antidepressant effects through neuroplastic adaptations, but their hallucinogenic properties remain a major obstacle to their widespread therapeutic use. In this study, we characterized a novel class of halogenated DMT derivatives—5-F-DMT, 5-Cl-DMT, and 5-Br-DMT—for their pharmacological activity, behavioral effects, and therapeutic potential. Using a combination of in vitro assays, in silico modeling, and in vivo behavioral and gene expression studies, we found that halogen substitution at the 5-position modulates receptor affinity and selectivity across key serotonin (5-HT) receptors (5-HT1A/2 A/2B/2CR) and transporter (SERT). Notably, 5-Br-DMT was found to activate 5-HT2AR but did not induce the head twitch response (HTR) in mice, suggesting non-hallucinogenic activity. Furthermore, 5-Br-DMT upregulated immediate early genes (IEGs) associated with neuroplasticity in the mouse prefrontal cortex and hippocampus (Arc, Egr-1, -2 and -3) and promoted dendritic growth in cortical neurons. In a mouse model of stress-induced depression, a single administration (10 mg/kg, i.p.) of 5-Br-DMT resulted in a significant reduction in depressive-like behavior, reflecting rapid antidepressant effects. Collectively, our results highlight 5-Br-DMT as a non-hallucinogenic psychoplastogen with antidepressant properties, supporting its potential as a prototypical candidate for further study. Moreover, the evaluation and biological characterization of the halogenated DMT derivatives offers valuable information on structure-activity relationships that may guide the design of future therapeutic compounds., info:eu-repo/semantics/publishedVersion
DAU Arxiu Digital de la Universitat Ramon Llull
Publicación Artículo científico (JournalArticle)

Structure-activity relationships of serotonergic 5-MeO-DMT derivatives: insights into psychoactive and thermoregulatory properties

  • Puigseslloses, Pol
  • Nadal Gratacós, Núria
  • Ketsela, Gabriel
  • Weiss, Nicola
  • Berzosa, Xavier
  • Estrada-Tejedor, Roger
  • Islam, Mohammad Nazmul
  • Holy, Marion
  • Niello, Marco
  • Pubill, David
  • Camarasa, Jordi
  • Escubedo, Elena
  • Sitte, Harald
  • López-Arnau, Raúl
Recent studies have sparked renewed interest in the therapeutic potential of psychedelics for treating depression and other mental health conditions. Simultaneously, the novel psychoactive substances (NPS) phenomenon, with a huge number of NPS emerging constantly, has changed remarkably the illicit drug market, being their scientific evaluation an urgent need. Thus, this study aims to elucidate the impact of amino-terminal modifications to the 5-MeO-DMT molecule on its interactions with serotonin receptors and transporters, as well as its psychoactive and thermoregulatory properties. Our findings demonstrated, using radioligand binding methodologies, that all examined 5-MeO-tryptamines exhibited selectivity for 5-HT1AR over 5-HT2AR. In fact, computational docking analyses predicted a better interaction in the 5-HT1AR binding pocket compared to 5-HT2AR. Our investigation also proved the interaction of these compounds with SERT, revealing that the molecular size of the amino group significantly influenced their affinity. Subsequent experiments involving serotonin uptake, electrophysiology, and superfusion release assays confirmed 5-MeO-pyr-T as the most potent partial 5-HT releaser tested. All tested tryptamines elicited, to some degree, the head twitch response (HTR) in mice, indicative of a potential hallucinogenic effect and mainly mediated by 5-HT2AR activation. However, 5-HT1AR was also shown to be implicated in the hallucinogenic effect, and its activation attenuated the HTR. In fact, tryptamines that produced a higher hypothermic response, mediated by 5-HT1AR, tended to exhibit a lower hallucinogenic effect, highlighting the opposite role of both 5-HT receptors. Moreover, although some 5-MeO-tryptamines elicited very low HTR, they still act as potent 5-HT2AR agonists. In summary, this research offers a comprehensive understanding of the psychopharmacological profile of various amino-substituted 5-MeO-tryptamines, keeping structural aspects in focus and accumulating valuable data in the frame of NPS. Moreover, the unique characteristics of some 5-MeO-tryptamines render them intriguing molecules as mixed-action drugs and provide insight within the search of non-hallucinogenic but 5-HT2AR ligands as therapeutical agents., info:eu-repo/semantics/publishedVersion
DAU Arxiu Digital de la Universitat Ramon Llull
Publicación Artículo científico (JournalArticle)

Pharmacological characterization of 4-F-3-Me-α-PVP: A novel synthetic cathinone with psychostimulant effects and abuse liability in rodents

  • Nadal-Gratacós, Núria
  • Pain, Stephanie
  • Mata, Sandra
  • Puigseslloses, Pol
  • De Macedo, Morgane
  • Lardeux, Virginie
  • WANG, Fu-Hua
  • Källsten, Liselott
  • Pubill, David
  • Berzosa, Xavier
  • Kehr, Jan
  • Solinas, Marcello
  • Escubedo, Elena
  • Camarasa, Jordi
  • López-Arnau, Raúl
Background: The continual emergence of novel synthetic cathinones poses significant public health concerns due to their unpredictable pharmacological profiles and potential for abuse. Among these, 4-F-3-Me-α-PVP—a newly identified analogue of α-PVP—has recently surfaced on the illicit drug market, yet its biological effects remain uncharacterized. Aim: To provide the first comprehensive pharmacological evaluation of 4-F-3-Me-α-PVP. Methods: In vitro transporter inhibition was assessed using HEK293 cells expressing human dopamine (DA), norepinephrine, and serotonin transporter (DAT, NET, or SERT). In male rodents, locomotor activity was measured after i.p. (mice) or s.c. (rats) administration. In vivo microdialysis in rats quantified extracellular DA in the nucleus accumbens. Rewarding and reinforcing effects were evaluated using conditioned place preference (CPP) in mice and intravenous self-administration (IVSA) in rats under fixed-ratio and progressive-ratio schedules. Results: In vitro assays revealed that 4-F-3-Me-α-PVP acts as a potent DAT and NET inhibitor, with additional, though weaker, activity at SERT. In vivo, 4-F-3-Me-α-PVP significantly increased locomotor activity in male rodents (10 and 30 mg/kg in mice; 3 mg/kg in rats). Importantly, 4-F-3-Me-α-PVP also increased extracellular DA levels in the rat nucleus accumbens (3 mg/kg, s.c.), pointing to its potential for abuse. Behavioral assays further demonstrated rewarding and reinforcing effects in rodents, with significant CPP in mice at all doses tested and dose-dependent IVSA in rats observed under both fixed-ratio and progressive-ratio schedules. Conclusions: Collectively, these findings indicate that 4-F-3-Me-α-PVP possesses substantial psychostimulant and abuse-related effects in rodents, underscoring the need for regulatory vigilance and continued investigation into emerging synthetic cathinones., info:eu-repo/semantics/publishedVersion
DAU Arxiu Digital de la Universitat Ramon Llull
Publicación Artículo científico (JournalArticle)

The psychedelic phenethylamine 25C-NBF, a selective 5-HT2A agonist, shows psychoplastogenic properties and rapid antidepressant effects in male rodents

  • Nadal-Gratacós, Núria
  • Puigseslloses, Pol
  • Guzmán, Laura
  • Weiss, Nicola
  • Pottie , Eline
  • Riera Colomer, Clara
  • Lardeux, Virginie
  • THIRIET, Nathalie
  • Wang, Fu-Hua
  • Källsten, Liselott
  • Pérez-Esteban, Irene
  • Ketsela, Gabriel
  • Margall, Joel
  • Berzosa, Xavier
  • Pubill, David
  • Rodríguez-Arias, Marta
  • Ettcheto, Miren
  • Kehr, Jan
  • Stove, Christophe
  • Solinas, Marcello
  • Sitte, Harald
  • Escubedo, Elena
  • López-Arnau, Raúl
Psychedelics have garnered significant interest for their therapeutic potential in mental health conditions such as depression, anxiety, and post-traumatic stress disorder. While research has primarily focused on well-studied psychedelics, phenethylamine derivatives have also gathered interest for their potential therapeutic applications. Thus, this study aims to investigate the pharmacological profile, safety and therapeutic potential of novel N-(2-fluorobenzyl) phenethylamine analogs (NBFs) of the 2C-X series—25C-NBF, 25B-NBF, and 25I-NBF. NBFs displayed high affinity and selectivity for the 5-HT2A receptor and demonstrated bias factors (defined in our study as the preference for Gq over β-arrestin pathways at 5-HT2A receptor) similar to that of 5-HT. Acute administration induced moderate head-twitch responses without affecting locomotion or pre-pulse inhibition. Our studies revealed no rewarding effects in mice nor reinforcing effects or changes in accumbal dopamine levels in rats after NBFs administration. Further characterization of 25C-NBF revealed psychoplastogenic effects (dendritogenesis, spinogenesis and increased Bdnf mRNA levels) both in vitro and in vivo. In addition, 25C-NBF reduced despair-like behavior in response to acute stress and exerted rapid antidepressant effects in a model of anhedonia-like behavior induced by chronic corticosterone administration. Taken together, these findings suggest that 25C-NBF, and further analogs, may hold potential as novel antidepressants with a rapid onset of action and a favorable safety profile in terms of no abuse potential or sensorimotor gating deficits., info:eu-repo/semantics/publishedVersion
DAU Arxiu Digital de la Universitat Ramon Llull
Publicación Artículo científico (JournalArticle)

Unveiling the potential abuse liability of α-D2PV: A novel α-carbon phenyl-substituted synthetic cathinone

  • Nadal-Gratacós, Núria
  • Mata, Sandra
  • Puigseslloses, Pol
  • De Macedo, Morgane
  • Lardeux, Virginie
  • Pain, Stephanie
  • Wang, Fu-Hua
  • Källsten, Liselott
  • Pubill, David
  • Berzosa, Xavier
  • Kehr, Jan
  • Solinas, Marcello
  • Camarasa, Jordi
  • Escubedo, Elena
  • López-Arnau, Raúl
Synthetic cathinones are emerging psychoactive substances designed to mimic the effects of classical psychostimulants. Among them, α-D2PV, a novel pyrrolidine-containing cathinone characterized by a phenyl group on the α-carbon atom, has gained significant attention. This study investigates the in vitro and in silico mechanism of action as well as the abuse liability of α-D2PV using rodent models. Dopamine (DA), noradrenaline (NE), and serotonin (5-HT) uptake inhibition assays were conducted in HEK293 cells expressing the corresponding human monoamine transporter, complemented by molecular docking studies at the DA transporter (DAT). Behavioral studies in male Swiss CD-1 mice assessed locomotor activity and conditioned place preference, while microdialysis and self-administration experiments were performed in male Sprague-Dawley rats. The findings reveal that α-D2PV is a potent DA and NE uptake inhibitor, with minimal activity at the 5-HT transporter (SERT). Docking studies showed that the benzene rings of α-PVP and α-D2PV align precisely in their most stable conformations at DAT. In vivo, α-D2PV elicited dose-dependent hyperlocomotion, thigmotaxis, and rewarding effects in mice, alongside increased extracellular DA levels in the nucleus accumbens of awake rats. Self-administration experiments confirmed α-D2PV's high reinforcing efficacy, indicating a significant risk of abuse in humans. Finally, these results underscore the necessity for continued surveillance of α-D2PV within the illicit drug market. Furthermore, novel synthetic cathinones incorporating a phenyl ring at the α-carbon side chain warrant proactive monitoring due to their potential to retain dopaminergic activity and evade initial legal controls., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Neurochemical and behavioral evidence of high abuse liability of 3F-NEB, a novel synthetic cathinone

  • Pain, Stephanie
  • Nadal-Gratacós, Núria
  • De Macedo, Morgane
  • Lardeux, Virginie
  • Mata, Sandra
  • Puigseslloses, Pol
  • Wang, Fua-Hua
  • Källsten, Liselott
  • Pubill, David
  • Berzosa, Xavier
  • Kehr, Jan
  • Camarasa, Jorge
  • Escubedo, Elena
  • López-Arnau, Raúl
  • THIRIET, Nathalie
  • Solinas, Marcello
Synthetic cathinones constitute a major class of New Psychoactive Substances (NPS) with significant abuse potential. Within this class, 3F-N-ethylbuphedrone (3F-NEB or 2-(ethylamino)-1-(3-fluorophenyl)butan-1-one), a novel N-ethyl buphedrone derivative, has recently emerged in recreational drug markets. However, its pharmacological properties and abuse liability remain uncharacterized. The present study aimed to evaluate the neurochemical mechanisms and behavioral effects of 3F-NEB to assess its potential for abuse and addiction. To this end, we conducted in vitro monoamine uptake inhibition assays and in mice we performed locomotor activity and conditioned place preference tests. In rats, we conducted in vivo microdialysis in the nucleus accumbens, intravenous self-administration, and assessed neuroadaptive changes by ΔFosB immunohistochemistry following chronic self-administration. Our results demonstrate that 3F-NEB acts as a potent dopamine transporter (DAT) inhibitor, with more than 100-fold selectivity over the serotonin transporter (SERT). Acute administration (3 mg/kg) rapidly increased extracellular dopamine levels in the nucleus accumbens of rats. At the behavioral level, 3F-NEB induced dose-dependent locomotor increases (10–30 mg/kg), with anxiety-like effects at the highest doses, and conditioned place preference at all tested doses (3–30 mg/kg) in mice. 3F-NEB was readily self-administered by rats under both fixed-ratio and progressive-ratio schedules. Furthermore, chronic self-administration significantly increased ΔFosB expression in dorsomedial and dorsolateral striatum, mirroring patterns observed with methamphetamine. Taken together, these results demonstrate that 3F-NEB exhibits potent dopaminergic activity and high abuse liability through selective dopamine transporter inhibition. The compound's robust reinforcing properties and induction of addiction-related molecular adaptations suggest significant public health risks warranting immediate regulatory control., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

The psychedelic phenethylamine 25C-NBF, a selective 5-HT2A agonist, shows psychoplastogenic properties and rapid antidepressant effects in male rodents

  • Nadal-Gratacós, Núria
  • Puigseslloses, Pol
  • Guzmán, Laura
  • Weiss, Nicola
  • Pottie , Eline
  • Riera Colomer, Clara
  • Lardeux, Virginie
  • THIRIET, Nathalie
  • Wang, Fu-Hua
  • Källsten, Liselott
  • Pérez-Esteban, Irene
  • Ketsela, Gabriel
  • Margall, Joel
  • Berzosa, Xavier
  • Pubill, David
  • Rodríguez-Arias, Marta
  • Ettcheto, Miren
  • Kehr, Jan
  • Stove, Christophe
  • Solinas, Marcello
  • Sitte, Harald
  • Escubedo, Elena
  • López-Arnau, Raúl
Psychedelics have garnered significant interest for their therapeutic potential in mental health conditions such as depression, anxiety, and post-traumatic stress disorder. While research has primarily focused on well-studied psychedelics, phenethylamine derivatives have also gathered interest for their potential therapeutic applications. Thus, this study aims to investigate the pharmacological profile, safety and therapeutic potential of novel N-(2-fluorobenzyl) phenethylamine analogs (NBFs) of the 2C-X series—25C-NBF, 25B-NBF, and 25I-NBF. NBFs displayed high affinity and selectivity for the 5-HT2A receptor and demonstrated bias factors (defined in our study as the preference for Gq over β-arrestin pathways at 5-HT2A receptor) similar to that of 5-HT. Acute administration induced moderate head-twitch responses without affecting locomotion or pre-pulse inhibition. Our studies revealed no rewarding effects in mice nor reinforcing effects or changes in accumbal dopamine levels in rats after NBFs administration. Further characterization of 25C-NBF revealed psychoplastogenic effects (dendritogenesis, spinogenesis and increased Bdnf mRNA levels) both in vitro and in vivo. In addition, 25C-NBF reduced despair-like behavior in response to acute stress and exerted rapid antidepressant effects in a model of anhedonia-like behavior induced by chronic corticosterone administration. Taken together, these findings suggest that 25C-NBF, and further analogs, may hold potential as novel antidepressants with a rapid onset of action and a favorable safety profile in terms of no abuse potential or sensorimotor gating deficits., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Neuropharmacology of halogenated DMT analogs: psychoplastogenic and antidepressant properties of 5-Br-DMT, a psychedelic derivative with low hallucinogenic potential

  • Puigseslloses, Pol
  • Nadal-Gratacós, Núria
  • Fumas, Berta
  • Modenutti, Carlos Pablo
  • Pottie , Eline
  • Ortigosa, Juan Rodrigo
  • Pablo-Quesada, Albert
  • Riera Colomer, Clara
  • Ettcheto, Miren
  • Berzosa, Xavier
  • Pubill, David
  • Stove, Christophe
  • Escubedo, Elena
  • López-Arnau, Raúl
Current first-line antidepressants, such as selective serotonin reuptake inhibitors (SSRI), often present a delayed onset of action and fail to effectively treat a large proportion of patients, leaving a gap in the treatment of mood disorders. Psychedelics have recently emerged as promising alternatives due to their ability to produce fast-acting antidepressant effects through neuroplastic adaptations, but their hallucinogenic properties remain a major obstacle to their widespread therapeutic use. In this study, we characterized a novel class of halogenated DMT derivatives—5-F-DMT, 5-Cl-DMT, and 5-Br-DMT—for their pharmacological activity, behavioral effects, and therapeutic potential. Using a combination of in vitro assays, in silico modeling, and in vivo behavioral and gene expression studies, we found that halogen substitution at the 5-position modulates receptor affinity and selectivity across key serotonin (5-HT) receptors (5-HT1A/2 A/2B/2CR) and transporter (SERT). Notably, 5-Br-DMT was found to activate 5-HT2AR but did not induce the head twitch response (HTR) in mice, suggesting non-hallucinogenic activity. Furthermore, 5-Br-DMT upregulated immediate early genes (IEGs) associated with neuroplasticity in the mouse prefrontal cortex and hippocampus (Arc, Egr-1, -2 and -3) and promoted dendritic growth in cortical neurons. In a mouse model of stress-induced depression, a single administration (10 mg/kg, i.p.) of 5-Br-DMT resulted in a significant reduction in depressive-like behavior, reflecting rapid antidepressant effects. Collectively, our results highlight 5-Br-DMT as a non-hallucinogenic psychoplastogen with antidepressant properties, supporting its potential as a prototypical candidate for further study. Moreover, the evaluation and biological characterization of the halogenated DMT derivatives offers valuable information on structure-activity relationships that may guide the design of future therapeutic compounds., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Pharmacological characterization of 4-F-3-Me-α-PVP: A novel synthetic cathinone with psychostimulant effects and abuse liability in rodents

  • Nadal-Gratacós, Núria
  • Pain, Stephanie
  • Mata, Sandra
  • Puigseslloses, Pol
  • De Macedo, Morgane
  • Lardeux, Virginie
  • WANG, Fu-Hua
  • Källsten, Liselott
  • Pubill, David
  • Berzosa, Xavier
  • Kehr, Jan
  • Solinas, Marcello
  • Escubedo, Elena
  • Camarasa, Jordi
  • López-Arnau, Raúl
Background: The continual emergence of novel synthetic cathinones poses significant public health concerns due to their unpredictable pharmacological profiles and potential for abuse. Among these, 4-F-3-Me-α-PVP—a newly identified analogue of α-PVP—has recently surfaced on the illicit drug market, yet its biological effects remain uncharacterized. Aim: To provide the first comprehensive pharmacological evaluation of 4-F-3-Me-α-PVP. Methods: In vitro transporter inhibition was assessed using HEK293 cells expressing human dopamine (DA), norepinephrine, and serotonin transporter (DAT, NET, or SERT). In male rodents, locomotor activity was measured after i.p. (mice) or s.c. (rats) administration. In vivo microdialysis in rats quantified extracellular DA in the nucleus accumbens. Rewarding and reinforcing effects were evaluated using conditioned place preference (CPP) in mice and intravenous self-administration (IVSA) in rats under fixed-ratio and progressive-ratio schedules. Results: In vitro assays revealed that 4-F-3-Me-α-PVP acts as a potent DAT and NET inhibitor, with additional, though weaker, activity at SERT. In vivo, 4-F-3-Me-α-PVP significantly increased locomotor activity in male rodents (10 and 30 mg/kg in mice; 3 mg/kg in rats). Importantly, 4-F-3-Me-α-PVP also increased extracellular DA levels in the rat nucleus accumbens (3 mg/kg, s.c.), pointing to its potential for abuse. Behavioral assays further demonstrated rewarding and reinforcing effects in rodents, with significant CPP in mice at all doses tested and dose-dependent IVSA in rats observed under both fixed-ratio and progressive-ratio schedules. Conclusions: Collectively, these findings indicate that 4-F-3-Me-α-PVP possesses substantial psychostimulant and abuse-related effects in rodents, underscoring the need for regulatory vigilance and continued investigation into emerging synthetic cathinones., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Structure-activity relationships of serotonergic 5-MeO-DMT derivatives: insights into psychoactive and thermoregulatory properties

  • Puigseslloses, Pol
  • Nadal Gratacós, Núria
  • Ketsela, Gabriel
  • Weiss, Nicola
  • Berzosa, Xavier
  • Estrada-Tejedor, Roger
  • Islam, Mohammad Nazmul
  • Holy, Marion
  • Niello, Marco
  • Pubill, David
  • Camarasa, Jordi
  • Escubedo, Elena
  • Sitte, Harald
  • López-Arnau, Raúl
Recent studies have sparked renewed interest in the therapeutic potential of psychedelics for treating depression and other mental health conditions. Simultaneously, the novel psychoactive substances (NPS) phenomenon, with a huge number of NPS emerging constantly, has changed remarkably the illicit drug market, being their scientific evaluation an urgent need. Thus, this study aims to elucidate the impact of amino-terminal modifications to the 5-MeO-DMT molecule on its interactions with serotonin receptors and transporters, as well as its psychoactive and thermoregulatory properties. Our findings demonstrated, using radioligand binding methodologies, that all examined 5-MeO-tryptamines exhibited selectivity for 5-HT1AR over 5-HT2AR. In fact, computational docking analyses predicted a better interaction in the 5-HT1AR binding pocket compared to 5-HT2AR. Our investigation also proved the interaction of these compounds with SERT, revealing that the molecular size of the amino group significantly influenced their affinity. Subsequent experiments involving serotonin uptake, electrophysiology, and superfusion release assays confirmed 5-MeO-pyr-T as the most potent partial 5-HT releaser tested. All tested tryptamines elicited, to some degree, the head twitch response (HTR) in mice, indicative of a potential hallucinogenic effect and mainly mediated by 5-HT2AR activation. However, 5-HT1AR was also shown to be implicated in the hallucinogenic effect, and its activation attenuated the HTR. In fact, tryptamines that produced a higher hypothermic response, mediated by 5-HT1AR, tended to exhibit a lower hallucinogenic effect, highlighting the opposite role of both 5-HT receptors. Moreover, although some 5-MeO-tryptamines elicited very low HTR, they still act as potent 5-HT2AR agonists. In summary, this research offers a comprehensive understanding of the psychopharmacological profile of various amino-substituted 5-MeO-tryptamines, keeping structural aspects in focus and accumulating valuable data in the frame of NPS. Moreover, the unique characteristics of some 5-MeO-tryptamines render them intriguing molecules as mixed-action drugs and provide insight within the search of non-hallucinogenic but 5-HT2AR ligands as therapeutical agents., info:eu-repo/semantics/publishedVersion
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Unveiling the potential abuse liability of α-D2PV: A novel α-carbon phenyl-substituted synthetic cathinone

  • Nadal-Gratacós, Núria
  • Mata, Sandra
  • Puigseslloses, Pol
  • De Macedo, Morgane
  • Lardeux, Virginie
  • Pain, Stephanie
  • Wang, Fu-Hua
  • Källsten, Liselott
  • Pubill, David
  • Berzosa, Xavier
  • Kehr, Jan
  • Solinas, Marcello
  • Camarasa, Jordi
  • Escubedo, Elena
  • López-Arnau, Raúl
Synthetic cathinones are emerging psychoactive substances designed to mimic the effects of classical psychostimulants. Among them, α-D2PV, a novel pyrrolidine-containing cathinone characterized by a phenyl group on the α-carbon atom, has gained significant attention. This study investigates the in vitro and in silico mechanism of action as well as the abuse liability of α-D2PV using rodent models. Dopamine (DA), noradrenaline (NE), and serotonin (5-HT) uptake inhibition assays were conducted in HEK293 cells expressing the corresponding human monoamine transporter, complemented by molecular docking studies at the DA transporter (DAT). Behavioral studies in male Swiss CD-1 mice assessed locomotor activity and conditioned place preference, while microdialysis and self-administration experiments were performed in male Sprague-Dawley rats. The findings reveal that α-D2PV is a potent DA and NE uptake inhibitor, with minimal activity at the 5-HT transporter (SERT). Docking studies showed that the benzene rings of α-PVP and α-D2PV align precisely in their most stable conformations at DAT. In vivo, α-D2PV elicited dose-dependent hyperlocomotion, thigmotaxis, and rewarding effects in mice, alongside increased extracellular DA levels in the nucleus accumbens of awake rats. Self-administration experiments confirmed α-D2PV's high reinforcing efficacy, indicating a significant risk of abuse in humans. Finally, these results underscore the necessity for continued surveillance of α-D2PV within the illicit drug market. Furthermore, novel synthetic cathinones incorporating a phenyl ring at the α-carbon side chain warrant proactive monitoring due to their potential to retain dopaminergic activity and evade initial legal controls., info:eu-repo/semantics/publishedVersion